Introduction
Mutationally activated ras genes are the oncogene most frequently found in human tumors [1] . Mutated ras oncogenes have been identified in approximately 30% of all human tumors [2] , with over 90% in human pancreatic carcinomas and 50% in human colon cancers [3] . The three human ras genes (H-ras, N-ras, and K-ras) encode four low-molecular weight proteins (H-ras, N-ras, K-ras4B, K-ras4A) that function as guanosine diphosphate/guanosine triphosphate regulated switches in the transduction of growth-proliferative signals from the membrane to the nucleus [4] .
In order to perform its switching function in cell signaling, Ras must be located at the inner surface of the cell membrane [4] . This membrane anchorage occurs following farnesylation on the cysteine residue of the CAAX motif [4] . This CAAX motif is a common feature of all Ras proteins, composed of four amino acids at the carboxyl terminus (C = cysteine, A = valine, leucine, or isoleucine, X = methionine, or serine) [5] . Subsequent to farnesylation, the tripeptide AAX is proteolytically cleaved and the newly generated C-terminal cysteine is methylated [6] .
Farnesylation catalysed by the farnesyltransferase enzyme, a member of the prenyltransferase enzyme family, is therefore a key post-translational modification step for ras proteins and potential new antitumor agents have been designed which target this enzyme [7, 8] . One strategy was to develop peptides that could mimic the ras substrate recognition region for farnesyltransferase. These peptidomimetics of the ras CAAX motif are selective competitors to ras protein and inhibit ras protein farnesylation [8] .
A novel and potent family of nonpeptide tricyclic farnesyltransferase inhibitors, lacking a free sulfhydryl moiety, have been developed [9] [10] [11] [12] . In the present study, the activity of SCH 66336, a new compound of this family of nonpeptide tricyclic farnesyltransferase inhibitors, was tested against a large variety of human tumors to define preclinical activity profile, utilizing the human tumor cloning assay as previously described [13] . The cloning assay has shown the ability to distinguish clinically active from clinically inactive compounds [14] [15] [16] . In the present study, tumor specimens were taken both from patients who were untreated as well as those who had received prior therapy. These humans tumors were exposed to SCH 66336 in vitro and the response (^50% survival compared to untreated controls) was evaluated by quantitating the formation of human tumor colonyforming units. The use of the cloning system allows an estimation of the concentration and exposure which should be targeted to achieve antitumor activity, and to define human cancers that warrant phase II clinical trials with this compound.
Materials and methods
Ascitic, pleural, pericardial fluids and bone marrow aspirates were obtained by standard techniques. The fluid or marrow was placed in sterile containers containing 10 units of preservative-free heparin (O'Neill, Johns and Feldman, St. Louis, MO) per ml of malignant fluid or marrow After centrifugation at 150 g for 10 minutes, the cells were harvested and washed with McCoy's medium plus 10% heat-inactivated fetal calf serum. The viability of cell suspensions was determined on a hemocytometer with trypan blue. Only viable cells determined the final concentration of plated cells.
In vitro exposure of tumor cells to the drug Cells were suspended in 0.3% agar in enriched Connaught Medical Research Laboratories (CMRL) medium 1066 (Irvine Scientific, Irvine, CA) supplemented with 15% heat-inactivated horse serum, penicillin (100 units/ml), streptomycin (2 mg/ml), glutamine (2 mmol/1), insulin (3 units/ml), asparagine (0,6 mg/ml), and HEPES buffer (2 mmol/1). For continuous exposure, cells were combined with SCH 66336 in the CMRL medium, then plated in 35-mm Petri dishes in a top layer of agar over an underlayer of 0.3% agar to prevent growth of fibroblasts. Three plates were prepared for each data point. The compound was not washed from the culture during the two-week period and additional drug was not added to the culture. The plates were placed in a 37 °C incubator and removed on day 14 for colony count. The number of colonies, defined as more than 50 cells, formed on the three drug-treated plates were compared to the number of colonies formed on the three untreated control plates, and the percent colonies surviving at each concentration was calculated. An evaluable test is defined as one averaging at least 20 colonies on day 14 on the untreated control plates.
Drug
SCH 66336 was provided by Shering Plough Research Institute ( Figure I ). SCH 66336 was dissolved in DM SO to make a concentrated stock solution of 2.5 mg/ml. One-half milliliter (0.5 ml) aliquots of the stock solution were stored at -70 °C, and were thawed prior to testing each new tumor sample. At the time of testing, aliquots of the stock solution were further diluted to make the desired final concentrations. Four final concentrations of 0.1, 0.5, 1.0, and 2.5 uM were tested using continuous exposure (14 days). Continuous exposure was chosen in order to maintain drug concentrations above levels needed for complete inhibition of farnesyl transferase throughout the course of these studies. Furthermore, in vivo studies have shown tumor regression or tumor-growth inhibition upon extended oral treatment with SCH 66336 [17] . The tumor cells were also exposed to standard anticancer agents for 1 hour at the following concentrations (ng/ml): doxorubicin 0.04; cisplatin 0.2; etoposide 3.0; paclitaxel 2.5. The single concentration of each drug corresponded to approximatively 1/10 of the peak plasma concentration for each drug in humans [18] and was predictive of clinical response in previously published studies [16] . This information was not available for SCH 66336 and the corresponding values achievable in in vivo models served as a guidance [17] .
Human tumor colony-forming assay
After obtaining informed consent in accordance with federal and institutional guidelines, malignant effusions, ascites, bone marrow aspirates containing tumor cells as well as solid tumor specimens were collected from patients undergoing tissue procurement procedures as part of their diagnostic work-up or as part of their routine therapeutic care. Solid tumors or malignant lymph nodes were minced into 2 to 5 mm fragments in the operating room and immediately placed in McCoy's medium 5A (LifeTechnologies, Inc., Grand Island, NY) plus 10% heat inactivated newborn calf serum and 1% penicillin/streptomycin. Within four hours, these solid tumors were mechanically dissociated with scissors, forced through number 100 stainless steel mesh, through 25 gauge needles and then washed with McCoy's medium.
Quality control
To assure the presence of a single-cell suspension on the day of plating, positive controls were used to asses the effect on colony formation. For each tumor tissue sample tested, three positive control plates were set up to contain the non-specific cellular toxin orthosodium vanadate at a concentration of 200 ug/ml, which completely inhibits colony growth For a tumor sample test to be considered evaluable, orthosodium vanadate had to produce less than 30% survival of colony forming units when compared to untreated control plates. When survival was 5=30%, indicating that single-cell suspension on day 0 was poor since orthosodium vanadate does not affect clumps, the tumor sample test was considered non-evaluable. The use of a positive control has been demonstrated to greatly enhance the reproducibility of the human tumor cloning assay [14] .
The human tumor cloning assay is rigorously tested to eliminate the possibility of growing normal cells under the experimental conditions. Four criteria (colony must have > 50 cells, three replicates for each treatment group, at least 20 colonies must be formed, use of a vanadate control) are utilized to assure that only true colonies, and not cell clusters, are accounted for in the process of colony quantitation. Normal bone marrow cells are not capable of growing in soft agar.
A test is defined as an experiment, performed on a unique tumor tissue sample, that contains untreated control, positive control, and three to four specified drug concentration levels.
Data analysis and statistics
The results were expressed as the percentage of survival of tumor colony-forming units for a particular drug relative to its control. This quantity was calculated as the ratio of the average number of colonies surviving on the three drug-treated plates to the average number of colonies growing on the three untreated control plates. A ratio of ^ 0.5 denotes a positive response, suggesting a significant inhibition of colony formation by the drug. Statistical comparisons of the response rates were performed using the chi-square test with two-sided /"-values. A /"-value of <0.05 was considered to indicate statistical significance. Abbreviation. ACUP -adenocarcinoma of unknown origin. Sensitive defined as $ 50% survival at the given concentration.
Results

Evaluable specimens
One hundred and fifty specimens were treated with SCH 66336 at concentrations of 0.1,0.5, 1.0, and 2.5 uM using continuous exposure. Among these specimens, 46.6% (70 of 150) were evaluable with appropriate positive controls ( Table 1) .
In vitro responses
When SCH 66336 was evaluated at a concentration of 0.1 uM, in vitro responses (<50% survival compared to untreated controls) were observed in 17% (12 of 70) of the specimens (Table 1) . Positive response with < 30% of survival cells were observed in one stomach cancer sample.
With an exposure to 0.5 uM of SCH 66336, in vitro responses were observed in 19% (13 of 69) of the specimens (Table 1) . Positive response with < 30% of survival cells were observed in three specimens (bladder cancer, lymphoma, and stomach tumor colony forming units).
With regards to studies in 1.0 uM of SCH 66336 was evaluated, in vitro responses were noted in 31% (22 of 70) of the specimens (Table 1) . Positive response with < 30% of survival cells were observed in eight specimens (colon, lymphoma, melanoma, ovarian, pancreas, and Abbreviations: S/S -sensitive to both SCH 66336 and the agent; S/R -sensitive to SCH 66336 but resistant to the agent; R/S -resistant to SCH 66336 but sensitive to the agent; R/R -resistant to both SCH 66336 and the agent. Sensitive denned as < 50% survival at the given concentration. stomach tumor colony forming units, and two different tumor colony forming units of non-small-cell lung cancer).
When SCH 66336 was evaluated at a concentration of 2.5 uM, in vitro responses (=$50% survival compared to untreated controls) were observed in 41% (28 of 69) of the specimens (Table 1) . Positive response with < 30% of survival cells were observed in 14 different tumor colony forming units (Bladder cancer, breast cancer, colon cancer, lymphoma, melanoma, pancreas cancer, prostate cancer, and stomach cancer, three different non-smallcell lung cancers samples, and three different ovarian cancer samples).
There was a positive relationship between concentration and response to SCH 66336. There was a significant difference between the responses with 0.1 and 1.0 uM (P -0.02), between the responses with the two lowest concentrations (0.1 and 0.5 uM) and 2.5 uM (P = 0.0042 and 0.0091, respectively). There was no significant difference between the responses with 1.0 and 2.5 uM (P -0.34).
Tumor specificity
Inhibitory effects were obtained against multiple tumor types. With the highest concentration (2.5 uM), response was demonstrated in 50% (3 of 6) of breast tumors, 40% (6 of 15) of ovarian tumors, and 38% (5 of 13) of nonsmall-cell lung tumor colony forming units. There was also response with 2.5 uM of SCH 66336 in all the tested kidney (three of three), and prostate (two of two) tumor colony forming units (Table 1) .
Effects in tumors resistant to conventional chemotherapy
Among the 69 specimens tested at the concentration of 2.5 uM, SCH 66336 had activity in 4 of 15 (27%) tumor specimens that were resistant to doxorubicin, in 10 of 26 (38%) tumor specimens resistant to cisplatin, 7 of 21 (33%) tumor specimens resistant to paclitaxel, and 3 of 11 (27%) tumor specimens resistant to etoposide (Table 2) .
Discussion
In the present study using fresh tumors cultured in the human tumor cloning assay, SCH 66336 demonstrated prominent activity against various tumor types, including breast, ovarian, and non-small-cell lung tumor colony forming units. In addition, potential antitumor activity was also noted against kidney and prostate tumor colony forming units. Our results suggest that there is a direct relationship between concentration and response, with a significant difference between the responses with the two lowest concentrations (0.1 and 0.5 uM) and 2.5 uM (P -0.0042 and 0.0091, respectively). SCH 66336 was also tested in some tumor samples that have been shown to be resistant to classical anti-cancer drugs. The observed activity of SCH 66336 in 27% of tumors resistant to doxorubicin or etoposide, in 33% of tumors resistant to paclitaxel and in 38% of tumors resistant to cisplatin encourages additional testing of combinations and warrants testing the effects of SCH 66336, when conventional chemotherapy has failed.
Limitations of the human tumor cloning assay have been previously reviewed [14, 16] . Seventy tumor specimens out of 150 taken directly from patients (46.6%) were evaluable in the present study. A review on the method with 13,932 specimens demonstrated an overall evaluability of 35.2% [14] . Reproducible differences in cloning efficiencies exist between different tumor types. Certain histologic tumor types such as ovary, corpus uteri, kidney, and mesothelioma yield higher success rates in colony growth, while lymphoma, myeloma, digestive system, or endocrine tumors usually grow poorly [14] . A positive predictive value of 69% and a negative predictive value of 91% were demonstrated between in vitro response in the cloning assay and clinical response in individual patients [14] . Attempts have also been made to try to correlate in vitro phase II studies in the cloning assay and clinical phase II efficacy data [16] .
Many of the previous in vitro or in vivo studies on farnesyltransferase inhibitors were done on H-ras transformed cell lines or animals with a mutationally activated H-ras [19, 20] . However, most ras mutation in human tumors target K-ras rather than H or N-ras [1] . K-ras binds to farnesyltransferase about 10 times more tightly than H-ras [21] , and seems to be able to be efficiently processed by a type I geranylgeranyltransferase (GGTase-1), an other prenyltransferase enzyme, when farnesyltransferase is inhibited whereas H-ras can not [22, 23] . GGTase-1 also recognizes a CAAX motif, but when a leucine residue is in the X position [24] .
SCH 66336 is a member of a nonpeptide tricyclic farnesyltransferase inhibitors family [17] . This nonpeptidic nature seems to impart favorable stability to these compounds. Indeed, it has been reported that their IC50 values in cell-based assays was 5-20 times higher then their IC50 values in enzymatic assays whereas IC50 values of peptidomimetics in cell-based assays was 20-2000 times higher then their IC50 values in enzymatic assays [25, 26] . To obtain the same inhibition of anchorage-independent growth of rodent fibroblasts transformed with K-ras, compared to those transformed with H-ras, an increased concentration of 5-10 times was sufficient [27] .
Like other farnesyltransferase inhibitors, SCH 66336 also inhibits human tumor cell lines with the wild-type ras genotype, demonstrating that sensitivity to farnesyltransferase inhibitors does not correlate with the ras mutational status [27] . Efficacy of oral pharmacokinetic studies in animals with SCH 66336 demonstrated excellent oral bioavailability, and an intravenous half-life of 1.4 hour [28] . Plasma levels following oral doses of SCH resulted in peak values of 1.8-2.5 uM [28] , which is similar to the concentrations tested in our tumor cloning assay. Efficacy of orally administered SCH 66336 was demonstrated in nude mouse models with human tumor xenografts including tumors of colon, lung, pancreas, prostate and bladder [17] . SCH 66336 was also tested in Ha-ras transgenic mice with spontaneous occuring tumors [17] . In a preventive mode with treatment before tumor onset, orally SCH 66336 could delay the tumor onset and reduce the number of tumors per animal. In a therapeutic mode when the transgenic mice had developed palpable tumors, orally administered SCH 66336 induced tumor regression.
In summary, SCH 66336 has demonstrated potent in vitro cytotoxic activity against a broad spectrum of human tumors in the human tumor cloning assay. This drug is an orally bioavailable compound of the nonpeptide tricyclic farnesyltransferase inhibitor family and is currently undergoing clinical evaluation. The broad spectrum of tumor cell growth inhibition of SCH 66336 in the human tumor cloning assay, and more particularly against breast tumors, ovarian tumors, and non-smallcell lung tumor colony forming units, and its efficacy at physiologically relevant concentrations in animal models, suggest that SCH 66336 may deserve evaluation in future clinical trials in patients with ovarian, breast and non-small-cell lung cancer.
